560 related articles for article (PubMed ID: 17113983)
1. Prostate cancer risk in testosterone-treated men.
Raynaud JP
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):261-6. PubMed ID: 17113983
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
3. Testosterone deficiency syndrome: treatment and cancer risk.
Raynaud JP
J Steroid Biochem Mol Biol; 2009 Mar; 114(1-2):96-105. PubMed ID: 19429438
[TBL] [Abstract][Full Text] [Related]
4. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
Algarté-Génin M; Cussenot O; Costa P
Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer in men using testosterone supplementation.
Gaylis FD; Lin DW; Ignatoff JM; Amling CL; Tutrone RF; Cosgrove DJ
J Urol; 2005 Aug; 174(2):534-8; discussion 538. PubMed ID: 16006887
[TBL] [Abstract][Full Text] [Related]
6. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes.
Kaplan AL; Hu JC
Urology; 2013 Aug; 82(2):321-6. PubMed ID: 23706552
[TBL] [Abstract][Full Text] [Related]
7. Androgen replacement therapy and prostate safety.
Morales A
Eur Urol; 2002 Feb; 41(2):113-20. PubMed ID: 12074396
[TBL] [Abstract][Full Text] [Related]
8. Hormonal therapy of prostate cancer.
Labrie F
Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
[TBL] [Abstract][Full Text] [Related]
9. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
10. Testosterone replacement therapy and prostate risks: where's the beef?
Morgentaler A
Can J Urol; 2006 Feb; 13 Suppl 1():40-3. PubMed ID: 16526980
[TBL] [Abstract][Full Text] [Related]
11. Androgens and the ageing male.
Swerdloff RS; Wang C
Best Pract Res Clin Endocrinol Metab; 2004 Sep; 18(3):349-62. PubMed ID: 15261842
[TBL] [Abstract][Full Text] [Related]
12. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.
Haider A; Zitzmann M; Doros G; Isbarn H; Hammerer P; Yassin A
J Urol; 2015 Jan; 193(1):80-6. PubMed ID: 24980615
[TBL] [Abstract][Full Text] [Related]
13. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry.
Morales A
BJU Int; 2011 May; 107(9):1369-73. PubMed ID: 21518230
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
15. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
García-Cruz E; Piqueras M; Huguet J; Peri L; Izquierdo L; Musquera M; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
BJU Int; 2012 Dec; 110(11 Pt B):E541-6. PubMed ID: 22584031
[TBL] [Abstract][Full Text] [Related]
16. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
17. The influence of finasteride on the development of prostate cancer.
Thompson IM; Goodman PJ; Tangen CM; Lucia MS; Miller GJ; Ford LG; Lieber MM; Cespedes RD; Atkins JN; Lippman SM; Carlin SM; Ryan A; Szczepanek CM; Crowley JJ; Coltman CA
N Engl J Med; 2003 Jul; 349(3):215-24. PubMed ID: 12824459
[TBL] [Abstract][Full Text] [Related]
18. The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy.
Klap J; Schmid M; Loughlin KR
J Urol; 2015 Feb; 193(2):403-13. PubMed ID: 25260832
[TBL] [Abstract][Full Text] [Related]
19. Influence of radical prostatectomy on serum hormone levels.
Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
[TBL] [Abstract][Full Text] [Related]
20. ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale.
Lunenfeld B; Saad F; Hoesl CE
Aging Male; 2005 Jun; 8(2):59-74. PubMed ID: 16096160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]